BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Dapagliflozin
1
Role of sodium-glucose co-transporter 2 inhibitors in liver diseases
12/19/2025 8:32:37 AM | Browse: 74 | Download: 247
2
Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis
10/31/2024 7:40:50 AM | Browse: 169 | Download: 849
3
Advancing cardiovascular outcomes with dapagliflozin and sacubitril in post-acute myocardial infarction heart failure and type 2 diabetes mellitus
10/31/2024 7:21:20 AM | Browse: 164 | Download: 781
4
Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia
6/18/2024 9:29:50 AM | Browse: 195 | Download: 1008
5
Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience
3/15/2024 9:49:53 AM | Browse: 223 | Download: 914
6
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
11/24/2022 8:01:57 AM | Browse: 615 | Download: 1499
7
Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin
3/15/2022 2:23:07 PM | Browse: 709 | Download: 1922
8
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy
12/23/2021 6:10:00 AM | Browse: 620 | Download: 1098
9
Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
5/11/2020 9:58:04 AM | Browse: 1005 | Download: 1966
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.